TapImmune Inc.  

(Public, OTCMKTS:TPIV)   Watch this stock  
Find more results for David Bonfiglio
-0.005 (-0.86%)
Nov 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.57 - 0.59
52 week 0.12 - 1.71
Open 0.59
Vol / Avg. 84,355.00/599,527.00
Mkt cap 37.16M
P/E     -
Div/yield     -
EPS -0.71
Shares 64.62M
Beta 1.46
Inst. own 6%
Sep 9, 2015
TapImmune Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -3093.08% -20487.66%
Return on average equity - -
Employees 1 -
CDP Score - -


1551 Eastlake Ave E Ste 100
SEATTLE, WA 98102-7402
United States - Map
+1-206-5047278 (Phone)

Website links


TapImmune Inc. is a biotechnology company. The Company is focused on immunotherapy engaged in the development of peptide and gene-based immunotherapeutic and vaccines for the treatment of cancer and infectious disease. The Company's technologies include peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies, Polystart and TAP. The Company is focused on the clinical development and testing of its product candidates. The Company has two Phase I studies concluded at the Mayo Clinic, which are designed to evaluate the safety and immune response(s) of a set of HER2/neu antigens for a HER2/neu breast cancer vaccine and Folate Receptor Alpha for triple negative breast and ovarian cancer respectively. The Company is conducting preclinical studies for Polystart.

Officers and directors

Glynn Wilson Ph.D. Chairman of the Board, Chief Executive Officer, Chief Financial Officer, Secretary
Age: 68
Mark Reddish Vice President Development
Age: 60
John N. Bonfiglio Ph.D. Director
Age: 60
David Laskow-Pooley Director
Age: 58
Sherry Grisewood CFA Independent Director
Age: 62